Grzegorz S. Nowakowski, MD, Mayo Clinic

home / authors / grzegorz-s-nowakowski-md-mayo-clinic

Articles

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

May 25th 2023

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Treatment of R/R DLBCL: Beyond CAR T Therapy

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

RE-MIND Study in R/R DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

L-MIND Study in R/R DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

$Standard of Care for Relapsed/Refractory DLBCL$

Standard of Care for Relapsed/Refractory DLBCL

John M. Burke, MD, Rocky Mountain Cancer Centers;Julio Chavez, MD, Moffitt Cancer Center;Nathan H. Fowler, MD, MD Anderson Cancer Center;Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512